168 related articles for article (PubMed ID: 16403216)
1. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Marshall TG; Lee RE; Marshall FE
Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
[TBL] [Abstract][Full Text] [Related]
2. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
[TBL] [Abstract][Full Text] [Related]
5. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
[TBL] [Abstract][Full Text] [Related]
8. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Michel MC; Foster C; Brunner HR; Liu L
Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan is a potent target for prevention and treatment in human prostate cancer.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Oncol Rep; 2008 Aug; 20(2):295-300. PubMed ID: 18636189
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
11. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
12. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.
An J; Nakajima T; Kuba K; Kimura A
Hypertens Res; 2010 Aug; 33(8):831-5. PubMed ID: 20505677
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Mol Med Rep; 2009; 2(2):193-8. PubMed ID: 21475812
[TBL] [Abstract][Full Text] [Related]
15. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
Mizuno CS; Chittiboyina AG; Shah FH; Patny A; Kurtz TW; Pershadsingh HA; Speth RC; Karamyan VT; Carvalho PB; Avery MA
J Med Chem; 2010 Feb; 53(3):1076-85. PubMed ID: 20073471
[TBL] [Abstract][Full Text] [Related]
17. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
[TBL] [Abstract][Full Text] [Related]
18. A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Fujino M; Miura S; Kiya Y; Tominaga Y; Matsuo Y; Karnik SS; Saku K
Hypertens Res; 2010 Oct; 33(10):1044-52. PubMed ID: 20668453
[TBL] [Abstract][Full Text] [Related]
19. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
